Top Immutep Presentations
The most viewed presentations, reports, and documents from Immutep.
Immutep TACTI-003 Phase IIb Eftilagimod Alpha Pembrolizumab HNSCC
conferenceconference
1 Pages
Immutep TACTI-002 Eftilagimod Alpha Pembrolizumab NSCLC HNSCC Phase II
conferenceconference
1 Pages
Immutep AIPAC Trial Results: Eftilagimod Alpha with Paclitaxel in HR+ Breast Cancer
conferenceconference
1 Pages
Immutep AIPAC Phase IIb Eftilagimod Alpha Metastatic Breast Cancer Trial Results
conferenceconference
1 Pages
Immutep eftilagimod alpha pembrolizumab TACTI-002 NSCLC 2024
conferenceconference
8 Pages
Immutep TACTI-002 Eftilagimod Alpha Phase II Trial Results 2023
conferenceconference
9 Pages
Immutep AIPAC Phase IIb Eftilagimod Alpha Breast Cancer Biomarker Results
conferenceconference
1 Pages
Immutep TACTI-003 Phase IIb Trial Eftilagimod Alpha HNSCC 2024
conferenceconference
15 Pages
Immutep Limited Corporate Presentation 2024 - LAG-3 Immunotherapy
investor_presentationinvestor_presentation
60 Pages
Immutep LAG-3 Therapeutics Corporate Presentation December 2022
investor_presentationinvestor_presentation
33 Pages
Immutep 2023 Corporate Presentation - LAG-3 Immunotherapy
investor_presentationinvestor_presentation
34 Pages
Immutep Limited Corporate Presentation September 2023
investor_presentationinvestor_presentation
35 Pages
Immutep 2024 Corporate Presentation - LAG-3 Pipeline
investor_presentationinvestor_presentation
63 Pages
Immutep TACTI-002 eftilagimod alpha pembrolizumab HNSCC Phase II 2023
conferenceconference
1 Pages
Immutep TACTI-002 eftilagimod alpha pembrolizumab NSCLC Phase II 2022
conferenceconference
1 Pages
Immutep TACTI-003 Eftilagimod Alpha Head Neck Cancer Study Results
conferenceconference
14 Pages